Reviewer’s report

Title: Life-threatening gastrointestinal bleeding during targeted therapy for advanced renal cell carcinoma: a case report

Version: 2 Date: 7 February 2013

Reviewer: Axel Bex

Reviewer’s report:

The authors describe a case of severe GI bleeding following medication with temsirolimus for metastatic RCC.

Major comments: Case presentation: What do the authors mean by ‘patient was admitted for chemotherapy’? The case is presented as if the patient was admitted for diagnosis first.

It would be appropriate to list the metastatic sites and the subtype of renal carcinoma for completeness.

Why was an EGD performed before start of temsirolimus? Was there already a suspicion for some other pathology in the GI tract? Again, the authors should avoid the term chemotherapy here.

Last line of case report: the authors state that on repeat EGD improvement of GAVE was seen, while a few lines before they rule out any history of GAVE as the underlying cause and therefore claim it was due to temsirolimus. They should refer to an improvement of the GAVE-like lesions.

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I have been on advisory boards of Pfizer and received honoraria on an institutional account.